Physician profile
Edward A Steinmann
NPI 1528050622
$8,706.07
in general payments reported to CMS, 2019-2025
46 companies · $853 in 2025
The $853 reported for 2025 was more than what 97% of Chiropractor providers received nationally (typical 2025 total: $40.91).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $577 · 2021: $2,286 · 2022: $1,850 · 2023: $980 · 2024: $1,119 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,926 · Education: $24.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,926.44 |
| Education | $24.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,078.40 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $726.71 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $589.81 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $491.92 | 2019-2025 | |
| Novo Nordisk INC | $486.45 | 2020-2025 | Wegovy |
| Amgen INC. | $441.81 | 2019-2023 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $401.06 | 2021-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $340.66 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $296.48 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $240.09 | 2019-2024 | Austedo Xr |
| Antares Pharma, INC. | $215.12 | 2019-2023 | Tlando, Nocdurna, Xyosted |
| Allergan, INC. | $182.10 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $171.00 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $170.02 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $165.68 | 2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $137.66 | 2021-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $132.17 | 2019-2022 | |
| Abbott Laboratories | $116.52 | 2021-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $104.38 | 2019-2023 | Livalo, Seglentis |
| Biohaven Pharmaceuticals, INC. | $103.54 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.51 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $94.11 | 2021-2023 | Qelbree |
| Janssen Pharmaceuticals, INC | $92.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $78.48 | 2019-2025 | |
| Exact Sciences Corporation | $77.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Insulet Corporation | $59.80 | 2024-2025 | Omnipod |
| Actelion Pharmaceuticals US, INC. | $56.95 | 2023-2025 | Uptravi, Opsumit |
| Neos Therapeutics, LP | $54.01 | 2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Mayne Pharma Commercial LLC | $50.81 | 2023 | |
| Baxter Healthcare | $47.20 | 2022 | |
| Therapeuticsmd, INC. | $43.80 | 2021 | |
| Shire North American Group INC | $42.37 | 2019 | |
| Itamar Medical INC | $40.93 | 2024-2025 | Watchpatone |
| Sunovion Pharmaceuticals INC. | $35.14 | 2022 | |
| Mdd US Operations, LLC | $31.66 | 2025 | Qelbree |
| Lundbeck LLC | $31.13 | 2022 | |
| Idorsia Pharmaceuticals US INC | $28.80 | 2022-2023 | Quviviq |
| Biomarin Pharmaceutical INC. | $19.65 | 2021 | |
| Dexcom, INC. | $18.71 | 2023 | Dexcom G6 Transmitter |
| Coopersurgical, INC. | $18.57 | 2025 | Paragard T 380a |
| Sanofi Pasteur INC. | $17.66 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.45 | 2024 | Voquezna |
| Seqirus USA INC | $15.65 | 2024 | Flucelvax |
| Otsuka America Pharmaceutical, INC. | $15.54 | 2025 | Rexulti |
| Kaleo, INC. | $14.27 | 2022 | |
| Eisai INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Steinmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.